The FDA approved its first “biosimilar” drug, a decision expected to launch a new industry of lower-cost versions of expensive drugs that could help the U.S. curb its $300 billion in yearly drug spending.
WSJ.com: US Business, Wall Street Journal: Business
Fri, 03/06/2015 - 7:30am
The FDA approved its first “biosimilar” drug, a decision expected to launch a new industry of lower-cost versions of expensive drugs that could help the U.S. curb its $300 billion in yearly drug spending.